

Contents



DAVID WOODIN

EXECUTIVE PROFILE

32 Millennium's New Game Plan

Judith Sawyer, Managing Editor
CEO Mark Levin and his management team outline the company's new strategy: fewer partnerships, more focused R&D, and a push for profitability by 2006.



Prevailing notions about pharmacogenomics are mostly myths, page 70.

Features

Commentary

50 Why Pharma Branding Doesn't Work

Karl Schroff, Consultant
Every successful generic launch shows that patients are indifferent to innovators' brand efforts.

Business Strategies

60 Sharing IP, Sharing Risk

Carol Cherkis, NewCap Partners, & Paul J. Meyer, Jr., Squire, Sanders & Dempsey
To minimize the risks of cross-border alliances, intellectual property must be a priority.

Industry Trends

70 The Five Myths of Pharmacogenomics

Stan Bernard, Bernard Assocs.
Prevailing notions about PGx are often based on misconceptions. But in reality, the technology plays a vital role in pharma's business.

Communications

80 Making the Most of Advisory Meetings

Mark Zitter, the Zitter Group
Well designed programs can enhance pharma's success in managed care markets.

Cover photography by David Woodin. Art direction by Barbara Mickelson.

Contents continued on page 10

Contents continued

Marketers | Mix

NEWS

- 98 Thomson Titles
- 99 Improving the Pill
- 100 The Nag Factor

WINDOWS

- 99 People
- 100 Accounts in Action
- 102 Launches
- 102 Awards

COLUMNS

- 104 Commentary
- 106 Case Study
- 108 Industry Insider

FEATURE

- Benchmark Study**
- 110 **Trainers' Task: Do More with Less**
Michele Goldberg, Hay Insight, and Laura Ramos, *SPBT Focus* magazine
The Society of Pharmaceutical and Biotech Trainers reports the results of its fourth benchmarking study on training trends.

Features cont.


- Business Strategies**
- 84 **The Balanced Scorecard**
Gen Li, Pfizer
A new technology helps oversized R&D units manage operations and allocate resources.

Departments

- 18 **World Watch**
Generic biologics are not here yet, but researchers are getting closer on an anti-obesity pill.
- 26 **Washington Report**
FDA Revamps GMPs to Reflect Risk
Jill Wechsler
FDA offers new policies that encourage modern manufacturing and relate enforcement to risk.
- 30 **Euro Report**
UK Industry Urges Crackdown on Extremists
Sarah Houlton, PhD
Biotech companies want to make harassment from activists illegal.

120 People Update

124 Calendar



PE's Medical Education Meetings supplement helps CME providers prepare for the new guidelines.

Columns

- 14 **From the Editor**
No Easy Fix
Patrick Clinton
An extra ethics course won't combat corporate dishonesty.
- 16 **At Issue**
Pharma's Value Proposition
Humphrey Taylor, Harris Interactive
Pharma prices would be less of an issue if people thought they were a good value.
- 138 **Executive Edge**
Staying Out of the Woods
Josh Weinstein
A new cell phone service can keep you from getting lost.

Services

- 128 Advertisers
- 130 Professional Services